This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Arendrup, M. C.
Right arrow Articles by Donnelly, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Arendrup, M. C.
Right arrow Articles by Donnelly, J. P.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2009, p. 1628-1629, Vol. 53, No. 4
0066-4804/09/$08.00+0     doi:10.1128/AAC.01624-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Breakpoints for Susceptibility Testing Should Not Divide Wild-Type Distributions of Important Target Species{triangledown}

Maiken Cavling Arendrup,1* Gunnar Kahlmeter,2 Juan Luis Rodriguez-Tudela,3 and J. Peter Donnelly4

Unit of Mycology and Parasitology, Statens Serum Institut, Copenhagen, Denmark,1 Department of Clinical Microbiology, Central Hospital, Växjö, Sweden,2 Servicio de Micología, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Spain,3 Department of Haematology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands4

Received 10 December 2008/ Returned for modification 7 January 2009/ Accepted 25 January 2009

The fluconazole MIC distributions for Candida glabrata from testing 34 different clinical isolates and performing 51 tests on a single isolate mirrored each other. Since what is perceived as biological variation in isolates without resistance mechanisms is mainly methodological variation, breakpoints which divide this distribution not only lack a sound biological basis but also result in poor reproducibility of susceptibility characterization. This makes 2, 4, 8, and possibly 16 µg/ml unsuitable breakpoints for C. glabrata and fluconazole.

* Corresponding author. Mailing address: Unit of Mycology, Statens Serum Institut, Building 43/117, Artillerivej 5, DK-2300 Copenhagen, Denmark. Phone: 45 22632785. E-mail: mad{at}ssi.dk

{triangledown} Published ahead of print on 2 February 2009.

Antimicrobial Agents and Chemotherapy, April 2009, p. 1628-1629, Vol. 53, No. 4
0066-4804/09/$08.00+0     doi:10.1128/AAC.01624-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»